SPOTLIGHT: IG: FDA neglects oversight of human trials


The inspector general of the Department of Health and Human Services blasted the FDA's lax oversight of clinical trials, prompting experts to say rats and mice get better protection as research subjects than humans do. Release

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.